StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $5.60 | $5.29 | -5.54% | 1.3M |
| 05-18 | $5.41 | $4.77 | -11.83% | 2.4M |
| 05-19 | $4.73 | $4.45 | -5.92% | 1.3M |
| 05-20 | $4.49 | $4.57 | +1.78% | 1.1M |
| 05-21 | $4.54 | $4.60 | +1.32% | 0.8M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2019 2019-12-31 | Annual 2018 2018-12-31 |
|---|---|---|
Revenue | $0.00 | $0.00 |
Operating Income | $-16.39M | $-12.69M |
Net Income | $-16.39M | $-12.69M |
EPS (Diluted) | Not available | Not available |
Total Assets | $21.08M | $19.08M |
Total Liabilities | $3.03M | $3.28M |
Cash & Equivalents | $16.66M | $9.52M |
Free Cash Flow OCF − CapEx | $-15.27M | $-10.67M |
Shares Outstanding | 1.47M | 6.72M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.